Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for POLE-ultramutated endometrial cancer, drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Deciding which non-hotspot POLE variants are pathogenic.
Whether stage III and IV disease can also be de-escalated.
Making molecular classification universal outside a few countries.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
5-year OS 81.
Sensitivity 97%, NPV 99.